Home›Neurology› DEK emerges as neuron-specific ac4C-linked driver of neuroinflammation in Parkinson's disease
DEK emerges as neuron-specific ac4C-linked driver of neuroinflammation in Parkinson's diseaseNew research identifies a specific gene linked to Parkinson's disease
Frontiers in MedicinePublished September 10, 2026DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret DEK and BRD-K57589644 as computational and in vitro leads, not established Parkinson's therapies.
This publication reports a multi-omics analysis with in vitro validation focused on ac4C modification and neuroinflammation in Parkinson's disease. The stated aim was to identify a neuron-specific central pathogenic and therapeutic factor, with secondary goals of patient stratification, hub gene identification, diagnostic modeling, and therapeutic candidate discovery.
The analysis identified 7 ac4C-associated risk differentially expressed genes: HSP90AA1, DEK, LEF1, IRF2, BCL2L1, CFL1, and BCR. Patients were stratified into 2 distinct immune-molecular subgroups. DEK was identified as a neuron-distributed and up-regulated ac4C-associated central pathogenic factor. BRD-K57589644 was identified as a computationally prioritized compound.
Sample size, setting, comparator, follow-up, effect sizes, and p-values or confidence intervals were not reported. Adverse events, serious adverse events, discontinuations, and tolerability were not reported. Limitations and funding or conflicts were not reported. Certainty was not reported.
The association between DEK and ac4C or neuroinflammation is described as a computational and in vitro finding. The clinical efficacy of BRD-K57589644 is not established. Practice relevance is limited to hypothesis generation: DEK is proposed as a neuron-specific factor associated with ac4C modification and neuroinflammatory cascades in Parkinson's disease, and BRD-K57589644 is proposed as a potential therapeutic target.
How this fits prior evidence
Prior coverage has addressed Parkinson's disease through several distinct lenses: citicoline for motor improvement (OR 2.06 for minimal clinically important difference), robot-assisted gait training for balance and endurance, genetic associations including TLE4, HLA-V/HLA-G, and LRRK2 variants in East Asian cohorts, and IL-34/CSF1R signaling in CNS immune cell development and neurodegeneration. This multi-omics analysis extends the immune and genetic thread by proposing DEK as an ac4C-associated, neuron-distributed factor linked to neuroinflammatory cascades and by stratifying patients into 2 immune-molecular subgroups. It does not confirm or contrast with the symptomatic or rehabilitative findings, and no clinical outcomes are reported.
Living with Parkinson's disease involves dealing with constant inflammation in the brain. New research has identified a specific gene called DEK that plays a major role in this process. This gene is found throughout neurons and is linked to a specific chemical change that triggers harmful inflammation.
By looking at the molecular makeup of the disease, researchers were able to group patients into two distinct subgroups based on their immune and molecular profiles. This helps doctors understand that Parkinson's may not look the same for everyone. They also identified seven specific genes that are linked to the disease's progression.
While the study is still in the early stages of discovery, it successfully identified a specific compound called BRD-K57589644. This compound was chosen as a potential target for future treatments. Because this research used computer modeling and lab tests rather than human trials, the actual effectiveness of this drug in patients is not yet known.
What this means for you:
A specific gene called DEK is linked to brain inflammation in Parkinson's, offering a new target for drugs.
Common questions
What is the role of the DEK gene in Parkinson's?
The DEK gene is found throughout neurons and is linked to a specific chemical change that triggers harmful inflammation in the brain. It was identified as a central factor that contributes to the progression of Parkinson's disease.
Is the new drug BRD-K57589644 ready for patients?
Not yet. While BRD-K57589644 was identified as a promising target through computer modeling and lab tests, its actual effectiveness in people with Parkinson's has not been established in clinical trials.
Does this mean Parkinson's will be treated differently for different people?
The research suggests this is possible. By looking at molecular markers, researchers were able to group patients into two distinct subgroups based on their immune and molecular profiles, which could help in tailoring future treatments.
BackgroundEpi-transcriptomic modifications, particularly N4-acetylcytidine (ac4C), and chronic neuroinflammation have emerged as pivotal players in the pathogenesis of Parkinson’s disease (PD). However, the specific molecular co-expression patterns linking ac4C RNA modification to neuronal inflammatory responses remains largely uncharted.ObjectiveThis study aimed to decode the ac4C-neuroinflammation (AN)-associated molecular patterns in PD and to identify a neuron-specific central pathogenic and therapeutic factor.MethodsWe integrated multi-omics analyses by using peripheral blood bulk transcriptomes (GSE18838, GSE49126, GSE22491, GSE6613, and GSE57475) and GWAS data from PD patients for identification of AN-related risk genes. Next, consensus clustering and 3 machine learning algorithms (LASSO, RF, and SVM-RFE) were applied for patient stratification, hub gene identification, and diagnostic modeling. Single-cell transcriptomic profiling of PD patients (GSE140231) was leveraged to map the cellular distribution and mechanistic roles of the hub gene within the substantia nigra (SN). An AI-driven active learning framework and the CTD database were utilized to screen therapeutic candidates targeting the hub gene, with binding affinities validated via molecular docking. In vitro experiments finally validated the expression of hub gene.ResultsWe pinpointed 7 AN-associated risk DEGs for PD patients, including HSP90AA1, DEK, LEF1, IRF2, BCL2L1, CFL1, and BCR, which effectively stratified PD patients into 2 distinct immune-molecular subgroups. DEK can be considered as neuron-distributed and up-regulated AN-associated central pathogenic factor for PD patients. The DrugReflector active learning framework identified BRD-K57589644 as a computationally prioritized compound warranting further investigation.ConclusionThis study establishes a novel AN-associated molecular patterns in PD, identifying DEK as a computationally identified neuron-specific factor associated with ac4C modification and neuroinflammatory cascades for PD patients.
